Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Kennichi Satoh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1324-6387; OpenAlex author ID A5023367894, A5113142644. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
2
Collaborators
24
Papers, trials and grants by year

2012: 6 papers · 2013: 2 papers · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 18

  1. Applying Artificial Intelligence Technologies to Detect Pancreatic Ductal Adenocarcinoma Using Routine Laboratory Tests: A Pilot Study with the Aid of Machine … Last author DOI 10.2169/internalmedicine.7036-25↗
  2. Diffuse pancreatic parenchymal atrophy, an imaging finding predictive of the development of pancreatic ductal adenocarcinoma: A case-control study. Last author DOI 10.1002/jgh3.12930↗
  3. PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. Co-author DOI 10.1111/cas.15315↗
  4. Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics11020375↗
  5. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen spec… Last author DOI 10.3892/ijo.2018.4258↗
  6. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-014-0997-0↗
  7. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Last author DOI 10.3892/ijo.2014.2743↗
  8. [The molecular mechanism of the invasion and metastasis in the pancreatic ductal adenocarcinoma]. Co-author PMID 25856978↗
  9. MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Co-author DOI 10.1016/j.cellsig.2013.11.003↗
  10. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2013.12.019↗
  11. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. First author DOI 10.1002/jcp.24280↗
  12. [The molecular mechanism in tumorigenesis and development of pancreatic cancer]. Co-author PMID 24305091↗
  13. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. First author DOI 10.1002/jcp.22781↗
  14. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2012.04.014↗
  15. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. First author DOI 10.1158/1541-7786.mcr-11-0272↗
  16. [Pancreatic tumor: progress in diagnosis and treatment. Topics: I. Pancreatic carcinoma: 2. Pathogenesis and pathobiology in pancreatic cancer.--The molecular … Co-author DOI 10.2169/naika.101.7↗
  17. Regulators of epithelial mesenchymal transition in pancreatic cancer. First author DOI 10.3389/fphys.2012.00254↗
  18. MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphys.2012.00430↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tooru Shimosegawa · 11 shared papers, 2012–2015 · strength 0.52
  2. Shin Hamada · 10 shared papers, 2012–2015 · strength 0.46
  3. Akinobu Koiwai · 2 shared papers, 2023–2026 · strength 0.45
  4. Atsushi Masamune · 7 shared papers, 2012–2014 · strength 0.28
  5. Ikuro Sato · 3 shared papers, 2015–2022 · strength 0.24
  6. Keiichi Tamai · 3 shared papers, 2015–2022 · strength 0.24
  7. Shin Miura · 3 shared papers, 2013–2014 · strength 0.14
  8. Misa Yokoyama · 2 shared papers, 2015–2018 · strength 0.12
  9. Makoto Abue · 2 shared papers, 2015–2018 · strength 0.12
  10. Kazuhiro Kikuta · 4 shared papers, 2012–2013 · strength 0.12
  11. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
  12. Keiichi Jingu · 1 shared paper, 2022 · strength 0.12
  13. Katsuya Fukui · 1 shared paper, 2022 · strength 0.12
  14. Hiroshi Shima · 1 shared paper, 2022 · strength 0.12
  15. Toru Furukawa · 1 shared paper, 2022 · strength 0.12
  16. Atsushi Kanno · 3 shared papers, 2012–2013 · strength 0.09
  17. Jun Unno · 2 shared papers, 2012–2013 · strength 0.06
  18. Kazuo Sugamura · 1 shared paper, 2015 · strength 0.05
  19. Shinichi Egawa · 1 shared paper, 2013 · strength 0.03
  20. Michiaki Unno · 1 shared paper, 2013 · strength 0.03
  21. Fuyuhiko Motoi · 1 shared paper, 2013 · strength 0.03
  22. Tetsuya Takikawa · 1 shared paper, 2012 · strength 0.03
  23. Hiromichi Ito · 1 shared paper, 2012 · strength 0.03
  24. Masayoshi Kobune · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.